BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
BioVie提供的數據顯示，Bezisterim有可能以與阿爾茨海默氏病和生物標誌物終點相關的方式減輕炎症和恢復動態平衡
"Bezisterim" has been approved as the non-proprietary name for NE3107
Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation
“Bezisterim” 已被批准爲 NE3107 的非專有名稱
數據顯示 bezisterim 如何通過與癡呆、新陳代謝和炎症相關的特定基因恢復動態平衡
CARSON CITY, Nev., April 25, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including neurological and neuro-degenerative disorders and liver disease, today announced that an oral presentation and poster revealing additional data on how bezisterim potentially restores homeostasis was presented at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit held in Boston, Massachusetts April 23-25.
內華達州卡森城，2024年4月25日（GLOBE NEWSWIRE）——BioVie Inc.（納斯達克股票代碼：BIVI）（“BioVie” 或 “公司”）是一家臨床階段的公司，正在開發治療包括神經系統和神經退行性疾病以及肝病在內的慢性衰弱性疾病的創新藥物療法。該公司今天宣佈，一份口頭陳述和海報揭示了有關貝齊斯特里姆可能如何恢復的更多數據動態平衡是在4月23日至25日在馬薩諸塞州波士頓舉行的第十二屆阿爾茨海默氏症和帕金森氏症藥物研發年度峯會上發表的。
The presentation...
演示...
登入免費觀看全文
登入/註冊